Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques-Emmanuel Galimard

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
JCO Global Oncology|June 4, 2026
Landscape Assessment to Characterize Baseline Access and Multilevel Barriers to IMProve Access to Chimeric Antigen Receptor T-Cell CD19 Therapy for Pediatric B-ALL (IMPACT study) Across EuropeAleksandra Oszer, Jacques-Emmanuel Galimard, Joseph R Wardell, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Landscape assessment to characterize baseline access and multilevel barriers to IMProve Access to CAR-T CD19 therapy (IMPACT study) across EuropeAleksandra Oszer, Jacques-Emmanuel Galimard, Joseph R Wardell, et al.
Children (Basel, Switzerland)|August 27, 2021
Specialized Pediatric Palliative Care Services in Pediatric Hematopoietic Stem Cell Transplant CentersHilda Mekelenkamp, Teija Schröder, Eugenia Trigoso, et al.
Journal of Hematology & Oncology|May 8, 2020
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMTJaime Sanz, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Bone Marrow Transplantation|November 5, 2025
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMTVanderson Rocha, Myriam Labopin, Anna Maria Raiola, et al.
Blood Advances|January 9, 2023
Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT studyJoshua A Fein, Roni Shouval, Jacques-Emmanuel Galimard, et al.
Cancer|June 3, 2023
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party studyRama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Bone Marrow Transplantation|October 18, 2025
Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMTArnon Nagler, Jacques-Emmanuel Galimard, Sarah Kayser, et al.
Transplantation and Cellular Therapy|May 9, 2021
Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic LeukemiaAnnalisa Ruggeri, Jacques-Emmanuel Galimard, Olesya Paina, et al.
Blood|January 10, 2023
Rare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuriaPedro Henrique Prata, Jacques-Emmanuel Galimard, Flore Sicre de Fontbrune, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
JCO Global Oncology|June 4, 2026
Landscape Assessment to Characterize Baseline Access and Multilevel Barriers to IMProve Access to Chimeric Antigen Receptor T-Cell CD19 Therapy for Pediatric B-ALL (IMPACT study) Across EuropeAleksandra Oszer, Jacques-Emmanuel Galimard, Joseph R Wardell, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Landscape assessment to characterize baseline access and multilevel barriers to IMProve Access to CAR-T CD19 therapy (IMPACT study) across EuropeAleksandra Oszer, Jacques-Emmanuel Galimard, Joseph R Wardell, et al.
Children (Basel, Switzerland)|August 27, 2021
Specialized Pediatric Palliative Care Services in Pediatric Hematopoietic Stem Cell Transplant CentersHilda Mekelenkamp, Teija Schröder, Eugenia Trigoso, et al.
Journal of Hematology & Oncology|May 8, 2020
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMTJaime Sanz, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Bone Marrow Transplantation|November 5, 2025
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMTVanderson Rocha, Myriam Labopin, Anna Maria Raiola, et al.
Blood Advances|January 9, 2023
Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT studyJoshua A Fein, Roni Shouval, Jacques-Emmanuel Galimard, et al.
Cancer|June 3, 2023
Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party studyRama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, et al.
Bone Marrow Transplantation|October 18, 2025
Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMTArnon Nagler, Jacques-Emmanuel Galimard, Sarah Kayser, et al.
Transplantation and Cellular Therapy|May 9, 2021
Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic LeukemiaAnnalisa Ruggeri, Jacques-Emmanuel Galimard, Olesya Paina, et al.
Blood|January 10, 2023
Rare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuriaPedro Henrique Prata, Jacques-Emmanuel Galimard, Flore Sicre de Fontbrune, et al.
Pageof 8